Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Nuclear Receptor Signaling
|
April 11, 2006
Single-step purification of full-length human androgen receptor
Dalia Juzumiene, Ching-yi Chang, Daju Fan, et al.
The Prostate
|
December 19, 2018
HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer
Dorhyun Johng, Gonzalo Torga, Charles M Ewing, et al.
Molecular Cell
|
May 17, 2005
Structural basis for an unexpected mode of SERM-mediated ER antagonism
Ya-Ling Wu, Xiaojing Yang, Zhong Ren, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 4, 2009
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists
James D Joseph, Bryan M Wittmann, Mary A Dwyer, et al.
Molecular Cell
|
November 18, 2009
The homeodomain protein HOXB13 regulates the cellular response to androgens
John D Norris, Ching-Yi Chang, Bryan M Wittmann, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2022
A New Chemotype of Chemically Tractable Nonsteroidal Estrogens Based on a Thieno[2,3-<i>d</i>]pyrimidine Core
Vamshikrishna Reddy Sammeta, John D Norris, Sandeep Artham, et al.
Molecular Endocrinology (Baltimore, Md.)
|
May 23, 2009
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro
Daniel E Frigo, Andrea B Sherk, Bryan M Wittmann, et al.
Cancer Research
|
July 26, 2014
Obesity, cholesterol metabolism, and breast cancer pathogenesis
Donald P McDonnell, Sunghee Park, Matthew T Goulet, et al.
Breast Cancer Research and Treatment
|
September 29, 2019
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Suzanne E Wardell, Alexander P Yllanes, Christina A Chao, et al.
Breast Cancer Research and Treatment
|
November 18, 2019
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Suzanne E Wardell, Alexander P Yllanes, Christina A Chao, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Nuclear Receptor Signaling
|
April 11, 2006
Single-step purification of full-length human androgen receptor
Dalia Juzumiene, Ching-yi Chang, Daju Fan, et al.
The Prostate
|
December 19, 2018
HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer
Dorhyun Johng, Gonzalo Torga, Charles M Ewing, et al.
Molecular Cell
|
May 17, 2005
Structural basis for an unexpected mode of SERM-mediated ER antagonism
Ya-Ling Wu, Xiaojing Yang, Zhong Ren, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 4, 2009
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists
James D Joseph, Bryan M Wittmann, Mary A Dwyer, et al.
Molecular Cell
|
November 18, 2009
The homeodomain protein HOXB13 regulates the cellular response to androgens
John D Norris, Ching-Yi Chang, Bryan M Wittmann, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2022
A New Chemotype of Chemically Tractable Nonsteroidal Estrogens Based on a Thieno[2,3-<i>d</i>]pyrimidine Core
Vamshikrishna Reddy Sammeta, John D Norris, Sandeep Artham, et al.
Molecular Endocrinology (Baltimore, Md.)
|
May 23, 2009
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro
Daniel E Frigo, Andrea B Sherk, Bryan M Wittmann, et al.
Cancer Research
|
July 26, 2014
Obesity, cholesterol metabolism, and breast cancer pathogenesis
Donald P McDonnell, Sunghee Park, Matthew T Goulet, et al.
Breast Cancer Research and Treatment
|
September 29, 2019
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Suzanne E Wardell, Alexander P Yllanes, Christina A Chao, et al.
Breast Cancer Research and Treatment
|
November 18, 2019
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Suzanne E Wardell, Alexander P Yllanes, Christina A Chao, et al.
Page
of 4